表紙
市場調查報告書
商品編碼
1028763

癌症的標靶治療藥 - 肺癌

Targeted Oncology Therapeutics - Lung Cancers

出版日期: | 出版商: Greystone Research Associates | 英文 | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

現在,在約有2,000件臨床試驗進行的癌症治療領域,現有的製藥公司針對最近的治療方案的利益擴大開始快速行動。使用了新的途徑和訊號的12種標靶治療法,象徵癌症治療及抗惡性腫瘤治療的新時代。這些治療方法,尋求減輕肺癌造成的身體,心理,精神的負擔的治療方法,吸引許多醫藥品開發商。

本報告提供肺癌的標靶治療藥市場相關調查,市場概要,以及核准完畢治療藥趨勢,競爭情形,臨床試驗趨勢,及加入此市場的主要企業的簡介等資訊。

目錄

  • 內容概要
  • 摘要整理
  • 重組藥物的生態系統
  • 各地區的生技藥品趨勢
  • 腫瘤生物學市場領導
  • 腫瘤學mAb:競爭上的考慮事項
  • mAb及標的腫瘤治療
  • 生技藥品的歷史成長
  • 主要的生物製藥製造商-藥物及各市場區隔的活動
  • FDA批准的mAb適用於肺癌
  • FDA批准的TKI用於肺癌
  • 主要的治療標的
    • EGFR
    • VEGF
    • ALK遺傳基因
    • PD-L1
    • ROS-1遺傳基因
    • RET
  • 目標市場
  • 開發中的藥物
  • 主要的肺癌供應商的評估
目錄
Product Code: TRL474K

Targeted Oncology Therapies

The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from therapies that can ease the physical, psychological and emotional burden of lung cancers. This report examines two dozen therapeutic drugs targeting lung cancer, and the biomarkers they utilize.

What You Will Learn:

  • What is the market share of approved therapeutics?
  • What is the global supply picture for targeted therapeutics?
  • Who are the market leaders, by Indication? by Product?
  • What is the therapeutic coverage across all oncology indications? What are the product opportunities?
  • What are the established products in this space? by target, indication, API class, revenue?
  • What is the competitive picture for the major Oncology market segments?
  • Drug treatment resources
  • Competitive therapy map
  • Clinical trial activity
  • Who are the leading competitors in the field of next-generation therapeutics?

SAMPLE VIEW

Numerous Charts, Tables & Visualizations

Clear & Concise Market Segment Data

Table of Contents

  • Summary of Contents
  • Executive Summary
  • The Recombinant Drug Ecosystem
  • Biological Drug Activity by Region
  • Biological Oncology Market Leaders
  • Oncology mAbs: Competitive Considerations
  • mAbs and Targeted Oncology Therapeutics
  • Historical Growth of Biologicals
  • Leading Biological Drug Companies - Activity by Drug & Segment
  • FDA Approved mAbs Indicated for Lung Cancers
  • FDA Approved TKIs Indicated for Lung Cancers
  • Key Therapeutic Targets
    • EGFR
    • VEGF
    • ALK Gene
    • PD-L1
    • ROS-1 Gene
    • RET
  • The Addressable Market
  • Drugs in Development
  • Leading Lung Cancer Supplier Assessments